Announcement on behalf of subsidiary, OBIGEN, that OBI-858 completes its Phase I and demonstrates good safety, proceeding to Phase II as planned

1.Date of occurrence of the event:2021/11/30 2.New drug name or code:Novel Botulinum Neurotoxin, OBI-858 3.Indication:OBI-858, an in-house developed new botulinum neurotoxin (BoNT) product, is planned for aesthetic and therapeutic uses. BoNT is a protein neurotoxin produced by the bacterium, Clostridium botulinum, during the process of reproduction. It consists of a complex mixture of proteins containing […]